V
Visiopharm
AI-driven precision pathology and tissue image analysis software
About Visiopharm
In 2001, Johan Dore and Michael Grunkin founded Visiopharm in Denmark, setting out to revolutionize the field of digital pathology. Their vision was to harness the power of AI to enhance image analysis and workflow standardization in pathology labs. This innovation aimed to improve diagnostic accuracy and efficiency, addressing a critical need in medical diagnostics.
Read full description
Visiopharm's journey was marked by strategic growth and innovation. In 2016, the company expanded its capabilities by acquiring LRI Instrument AB, a move that strengthened its technological foundation and broadened its market reach. This acquisition was a pivotal moment, enabling Visiopharm to offer more comprehensive solutions to its clients.
Over the years, Visiopharm secured significant funding to fuel its growth. By 2025, the company had raised a total of $26.3 million over several funding rounds, attracting investments from notable entities like ATP and BankInvest. This financial backing was crucial in supporting Visiopharm's research and development efforts, allowing it to stay at the forefront of digital pathology innovation.
Today, Visiopharm stands as a leader in the field, known for its cutting-edge AI-driven solutions that empower pathologists worldwide. The company's commitment to advancing medical diagnostics continues to drive its success, making it a key player in the healthcare technology landscape.
At a glance
- Status
- Acquired
- Founded
- 2001
- Headquarters
- Hørsholm, Denmark
- Employees
- 91
- Open positions
- None listed
- Dealroom signal
- 64.8/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Analytics, Oncology
- Technology
- Artificial Intelligence, Big Data, Deep Tech, Machine Learning, Augmented Reality, Deep Learning, Nanotech, Computer Vision
- Business model
- SaaS
- Client focus
- b2b
- Investment activity
- 1 company, latest Dec 2016
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | May 2026 | $0 | — | Grundium | ↗ |
| LATE VC✓Equity / VC | Sep 2020 | $0 | — | BankInvest · C.L. Davids Fond og Samling · ATP · Northcap | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Visiopharm is 8.1K monthly website visits, up 20.9% over the last three months. Visiopharm's team declined 9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
UK Research and Innovation
Series A1 investor entered at this stage
ATP
Series B and later4 investors entered at this stage
Northcap
Vator
BankInvest- CSC.L. Davids Fond og Samling
Other known investors4 additional known investors
Grundium
Technical University of Denmark
Export and Investment Fund of Denmark
Market Maturation Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Visiopharm on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Visiopharm’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.